OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCP

Loading news article.

OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCP | WAPE

OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCP

Article summary

Related companies

Comments —